Pompe Disease Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight's, "Pompe Disease Pipeline Insights 2023" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pompe Disease pipeline landscape. It covers the Pompe Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pompe Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Pompe Disease Pipeline Report
• DelveInsight's Pompe Disease pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Pompe Disease treatment.
• The leading companies working in the Pompe Disease Market include Immusoft, Asklepios Biopharmaceutical, Oxyrane, Maze Therapeutics, Amicus Therapeutics, Spark Therapeutics, and others.
• Promising Pompe Disease Pipeline Therapies in the various stages of development include ALGLUCOSIDASE ALFA, ACTUS-101, GC301, AT845, BMN 701, and others.
• September 2023: Genzyme, a sanofi company announced a study of Phase 4 clinical trials for ALGLUCOSIDASE ALFA. To evaluate the effect of one-year Alglucosidase alfa treatment on motor function [Six-minute walk test (6MWT) and lung function predicted Forced vital capacity (FVC)] among Chinese Late Onset Pompe Disease patients above 5 years old.
• September 2023: Amicus Therapeutics announced a study of Phase 3 clinical trials for Cipaglucosidase Alfa, and Miglustat. This is a phase 3 double-blind randomized study to study the efficacy and safety of intravenous ATB200 Co-administered with oral AT2221 in adult subjects with Late Onset Pompe Disease compared with Alglucosidase Alfa/placebo.

Request a sample and discover the recent advances in Pompe Disease Treatment Drugs @ Pompe Disease Pipeline Report- https://www.delveinsight.com/report-store/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Pompe Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Pompe Disease NDA approvals (if any), and product development activities comprising the technology, Pompe Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Pompe Disease Overview
A rare genetic disorder, Pompe disease is characterized by the abnormal buildup, inside cells, of a complex sugar molecule called glycogen. This buildup impairs the workings of different organs and tissues, especially the heart and other kinds of muscle. Pompe disease also is known as glycogen storage disease type 2 (GSD2).

Find out more about Pompe Disease Therapeutics Assessment @ Pompe Disease Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pompe Disease Emerging Drugs Profile
• AT-GAA: Amicus Therapeutics
• SPK-3006: Spark Therapeutics

Pompe Disease Pipeline Therapeutics Assessment
There are approx. 15+ key companies which are developing the Pompe Disease therapies. The Pompe Disease companies which have their Pompe Disease drug candidates in the most advanced stage, i.e. pre-registration include, Amicus Therapeutics.

Pompe Disease Pipeline Segmentation
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Pompe Disease Pipeline Report Insights
• Pompe Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Learn more about the emerging Pompe Disease Pipeline Therapies @ Pompe Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Pompe Disease Pipeline Report
• Coverage- Global
• Pompe Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pompe Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Pompe Disease Companies- Immusoft, Asklepios Biopharmaceutical, Oxyrane, Maze Therapeutics, Amicus Therapeutics, Spark Therapeutics, and others.
• Pompe Disease Pipeline Therapies- ALGLUCOSIDASE ALFA, ACTUS-101, GC301, AT845, BMN 701, and others.

Dive deep into rich insights for new drugs for Pompe Disease Treatment, Visit @ Pompe Disease Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Pompe Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pompe Disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. Cipaglucosidase Alfa: Amicus Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SPK-3006: Spark Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. ACTUS-101: Asklepios Biopharmaceutical
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Pompe Disease Key Companies
24. Pompe Disease Key Products
25. Pompe Disease- Unmet Needs
26. Pompe Disease- Market Drivers and Barriers
27. Pompe Disease- Future Perspectives and Conclusion
28. Pompe Disease Analyst Views
29. Pompe Disease Key Companies
30. Appendix

For further information on the Pompe Disease Pipeline therapeutics, reach out to Pompe Disease Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/pompe-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

This release was published on openPR.